Xycota Biosciences Announces Nature Portfolio Publication Supporting Brain Repair Platform Targeting FTD and ALS
The Californer/10341721

BEVERLY HILLS, Calif. - Californer -- Xycota Biosciences, LLC ("Xycota"), an early-stage biotechnology company focused on brain repair therapeutics, today announced the formal unveiling of its neuro-restoration platform, anchored by newly published mechanistic evidence in the Nature Portfolio journal Neuropsychopharmacology.

The paper, "Psilocybin improves novel object recognition... through the modulation of the BDNF/TrkB signaling pathway" (Trezza, Hausman, et al., 2026), provides mechanistic evidence supporting the company's brain repair strategy: restoring synaptic function and neural circuitry by decoupling therapeutic effects from psychedelic receptor activity.

The "Big Unlock": Mechanistic Insight into Neural Repair

For decades, the therapeutic potential of psilocybin was assumed to be inseparable from its psychedelic effects. The Trezza-Hausman findings provide a strong translational rationale for challenging this paradigm. The research suggests that cognitive restoration may be mediated primarily through the BDNF/TrkB signaling pathway—the brain's intrinsic growth and repair circuitry—rather than hallucinogenic receptor pathways.

More on The Californer

• What Would you Do with Your Time if it Was Actually Money?
• Plaza Mexico Presents 'Golazo Fest'
• Mr. Hospital Bed Showcases the Best Hospital Bed and Air Mattress for Bed Sores for 2026
• The Packaging Company Expands Airless Pump Bottles for Cosmetic and Skincare Brands
• Traian TKD Tractari Auto Iasi: cum transporti legal la RAR o masina fara numere sau cu ITP expirat

"This discovery is the bedrock of Xycota," said Dr. Marvin S. Hausman, MD, Founder and CSO. "We have identified a biological signaling pathway that triggers neural repair. Xycota was formed to translate this insight into a standardized biological interface, allowing us to engineer restorative therapeutics without the psychedelic effects."

The FTD-ALS Continuum: A Strategic Clinical Roadmap

With the BDNF-TrkB mechanism supported by preclinical data, Xycota is focusing its primary development program on Frontotemporal Dementia (FTD). FTD is a catastrophic condition characterized by the progressive decay of synaptic connections, leading to the loss of judgment, personality, and cognitive independence.

Strategically, Xycota's focus on FTD provides a critical entry point into a broader spectrum of neurodegenerative disorders. FTD and Amyotrophic Lateral Sclerosis (ALS) are increasingly recognized as part of a clinical and pathological continuum, often sharing underlying synaptic vulnerabilities and protein pathologies. By establishing a translational signal of repair in FTD, Xycota plans to expand its platform to address the urgent unmet needs in ALS and other disorders where synaptic degeneration is a primary driver of decay.

More on The Californer

• California and federal government secure $3 million in refunds for mortgage fraud victims
• Ajala Sen Selected as Long Beach's Fourth Youth Poet Laureate
• Mike Williams Golf Center Now Open at Georgia's Lanier Islands Resort
• Chris Holt Photography Celebrates Studio Grand Opening with One-Day Headshot Event
• Appliance EMT Launches June "Summer Rescue" Promotion

Technology: Fungal-Derived Exosome Delivery

To translate these findings into a clinical reality, Xycota is developing a proprietary fungal-derived exosome delivery platform. This biological delivery vehicle is being engineered to improve CNS targeting and blood-brain barrier penetration, allowing for liver-bypass and more precise modulation of the BDNF pathway.

"Our goal is to move medicine from symptom management to the restoration of synaptic function," said Brad Listermann, President & Co-Founder. "By merging Dr. Hausman's 50-year track record in CNS development with this mechanistic evidence, Xycota is built to deliver a measurable signal of brain repair across multiple CNS disorders."

About Xycota Biosciences, LLC

Xycota Biosciences is an early-stage biotechnology company developing precision neuroplasticity therapeutics. Anchored by peer-reviewed science in the Nature Portfolio (Neuropsychopharmacology and npj Aging), Xycota is building a scalable translational platform to treat FTD, ALS, and mTBI through targeted synaptogenesis and neural repair.

For more information or to access the Strategic Data Room, visit https://xycota.com.